SLAMF7 and Miyoshi myopathy: Compared with CD38/CD3, BCMA/CD3, or CS1/CD3 nano BiTE, the BCMA/CS1/CD38/CD3 NanoMuTEs had significantly higher binding ability to MM cell lines and primary patient MM cells and induced greater activation of T-cells and T-cell-redirected MM cell lysis.